Explore Our Blog: Expert Articles and Updates​

Depression is one of the most common mental health conditions in the world and for some, finding the right treatment can be a long and difficult journey. At Segal Trials, we are actively researching new care options, including psychedelic-based approaches, to better understand how they might help people living with treatment-resistant depression.

What Is Treatment-Resistant Depression?
Treatment-resistant depression (TRD) refers to depression that doesn’t improve after trying two or more standard antidepressant treatments. This can leave individuals feeling frustrated, hopeless, and unsure of where to turn next.

That’s where clinical research plays a vital role.

Exploring Psychedelics in Research
Psychedelics have gained attention in recent years for their potential use in mental health care. While still under investigation, certain psychedelic compounds are being studied for how they may interact with the brain differently than traditional medications.

At Segal Trials, our research team is conducting a clinical study to evaluate one of these compounds in individuals who have not responded to other treatments for depression. The goal is to learn more about its effects, safety, and potential as a new care option.

Why Participate in a Clinical Study?
By joining a clinical trial, you’re not only exploring new options for your own care — you’re helping researchers and future patients, too. Participants in our studies often receive:

• Access to care from experienced medical staff
• No-cost study-related exams and procedures
• Compensation for time and travel (if eligible)

Who Can Join?

• Our current study is enrolling adults who:
• Are between the ages of 18 and 65
• Have been diagnosed with depression
• Have not responded well to previous treatments
• Every study has specific eligibility criteria. If you’re interested, you can see if you qualify here or contact us directly.

Shaping the Future of Mental Health Care
At Segal Trials, we’ve been dedicated to advancing mental health research since 1998. With over two decades of experience and a passionate team of experts, we’re proud to support new research that could change lives.

If you or someone you know is struggling with depression and looking for new options, a research study may be a step worth exploring.

👉 Explore Current Studies

In recent years, there has been a resurgence of interest in psychedelics as potential treatments for mental health disorders. Among the many substances being studied, N,N-Dimethyltryptamine (DMT) stands out due to its unique properties and rapid, intense effects. While traditionally associated with shamanic rituals and ayahuasca ceremonies, DMT is now being explored for its potential to alleviate anxiety. Could this powerful psychedelic be the key to unlocking relief for those struggling with anxiety disorders?

Welcome to Part 2 of our exploration into anxiety. Last year, we discussed common behaviors and symptoms associated with Social Anxiety Disorder in our blog: If You Can Relate, You May Have Social Anxiety Disorder. Today, we delve deeper, offering new insights and the latest information to help you understand this pervasive condition. If you find yourself relating to these experiences, it may be time to consider professional avenues, including potential participation in a clinical trial for anxiety.

Miami Lakes, FL – Segal Trials, a leading clinical research organization specializing in acute schizophrenia trials, has been recognized by the PPD Select Global Partnership Program for outstanding enrollment performance. This accolade was awarded for the site’s exemplary participation in the Phase 2 study of CVL-231 (Emraclidine), aimed at treating patients experiencing an acute exacerbation of psychosis.

[North Miami, FL – [August 21, 2024] – Segal Trials is proud to announce the completion of the first injection procedure in the DigniFI Study. The Women’s Health Team, under the leadership of Principal Investigator Steven Chavoustie, M.D., FACOG and Sub-Investigator Brittany Berre MSN, ARNP, FNP-C, worked diligently to prepare for this vital women's health study. The study's first injection procedure was performed on August 19, 2024.. Segal Trials also completed the first muscle tissue procurement procedure for the study on March 21, 2024.

The FDA's recent decision to pause the approval of MDMA-assisted therapy for PTSD is a reminder of the complexities in advancing groundbreaking treatments. While the...

Postpartum depression (PPD) continues to be a significant challenge affecting many new mothers, altering the joyous occasion of childbirth into a time of struggle and emotional turmoil. With advances in medical research, new treatment avenues are opening up, offering hope where traditional methods might fall short. One such promising field is the use of psychedelics in treating mood disorders like PPD.

In the wake of the COVID-19 pandemic, humanity has been ushered into what many might call a "new normal," a period marked by profound shifts in our way of life and, notably, in our collective mental health. The psychological aftermath of the pandemic, compounded by other life-altering events, has spotlighted an undeniable crisis: a dramatic surge in mental health issues, burdening an already overwhelmed and antiquated mental health treatment system. Traditional treatments for conditions like addiction, anxiety, depression, and PTSD have remained largely unchanged for decades, sparking a crucial conversation about the need for innovation in mental health care.

The resurgence of interest in psychedelics, once sidelined by regulatory crackdowns and societal skepticism, marks a pivotal turn in the quest for effective mental health treatments. Psychedelic drugs, encompassing substances like psilocybin (found in magic mushrooms), LSD, MDMA (ecstasy), and ayahuasca, have moved from the fringes of scientific inquiry to the forefront of innovative psychiatric research. This article delves into how psychedelics are revolutionizing the treatment of mental illnesses such as anxiety, depression, addiction, and PTSD, the limitations of current pharmaceutical options, and the promising horizon of psychedelic-assisted therapy, underscored by rigorous clinical research aiming for FDA approval.

Clinical trials have always been at the forefront of medical advancements. These carefully designed studies provide evidence for interventions, treatments, and diagnostic tests that form the foundation of modern medicine. As technology continues to evolve, clinical trials are also undergoing rapid transformations, giving rise to innovative methodologies and tools. Here, we delve into the future of clinical trials, focusing on the emerging trends that are redefining this critical field.